- ASC30 demonstrated placebo-adjusted weight loss of up to 7.7% in a recently completed 13-week U.S. Phase II study in participants with obesity or overweight, with better gastrointestinal ...

We recently published 10 Stocks With Effortless Double-, Triple-Digit Gains. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was ...

Almost half of UK consumers would trust AI to shop for them, survey suggests - Almost one third of shoppers (32%) wanted the control to review and cancel the purchase after selection, the study for ...

A multidisciplinary USC research team has identified new compounds that may target a key driver of brain inflammation linked to Alzheimer's disease. Their research just published in the Nature ...